Why cutting GLP-1 benefits could be a costly mistake for companies

    Employers are increasingly reducing coverage for expensive GLP-1 medications, such as Ozempic and Wegovy, to control rising healthcare costs, but new research suggests that excluding these drugs could…


    Already an INSIDER? Sign in.